Study makes exciting progress in elucidating the mechanisms of bortezomib in lymphoma
Monday, July 12, 2010 - 15:28
in Health & Medicine
A new study by researchers from the John Theurer Cancer Center at Hackensack University Medical Center sheds light on how bortezomib (VELCADE), the first in a new class of cancer drugs known as proteasome inhibitors, works in mantle cell lymphoma. The study also provides preliminary evidence for which patients might benefit most from bortezomib. Additionally, researchers demonstrate that biomarkers - the genes and proteins that indicate biological processes - might help guide the selection of patients for specific clinical trials and speed-up the development of targeted cancer drugs. The study, which is now published online, will also appear in the July issue of Leukemia & Lymphoma.